Key result
TIMIC immunosuppression linked to ~34-point lower CV death or heart transplantation vs. conventional therapy.
Why the study?
Long-term results of the Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy (TIMIC) trial protocol needed evaluation.
Does a 6-month course of immunosuppressive therapy with prednisone and azathioprine (TIMIC protocol) reduce long-term cardiovascular death and heart transplantation in patients with biopsy-proven virus-negative chronic inflammatory cardiomyopathy?
Cohort (n=255)
No
Does a 6-month course of immunosuppressive therapy with prednisone and azathioprine (TIMIC protocol) reduce long-term cardiovascular death and heart transplantation in patients with biopsy-proven virus-negative chronic inflammatory cardiomyopathy?
A 6-month course of tailored immunosuppressive therapy with prednisone and azathioprine provides durable 20-year improvements in left ventricular function and markedly reduces cardiovascular death, heart transplantation, and ICD implantation in patients with biopsy-proven virus-negative inflammatory cardiomyopathy, with relapses successfully responding to repeat treatment.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This is the first study on immunosuppression in inflammatory cardiomyopathy, describing the long-term efficacy of this treatment on cardiac dimension and function and on HF symptoms over a very long follow-up period (up to 20 years). Of note, similar functional improvements persisted over time also in patients with severe left ventricular dilation and dysfunction at the time of diagnosis.”
“The paper presents important long-term results of the randomized, placebo-controlled TIMIC trial initially published by Frustaci et al. in 2009. The previous study played a leading role in the current position of endomyocardial biopsy and immunosuppressive therapy in virus-negative myocarditis/inflammatory cardiomyopathy.”
May support TIMIC immunosuppression in virus-negative inflammatory cardiomyopathy; leaves open confirmation in larger randomized trials.
AIMS: Long-term results of the Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy (TIMIC) trial protocol have been evaluated. METHODS AND RESULTS: Eighty-five patients with endomyocardial biopsy-proven virus-negative chronic inflammatory cardiomyopathy were enrolled in the randomized, double-blind, placebo-controlled TIMIC trial and received prednisone and azathioprine (n = 43) vs. placebo (n = 42) for 6 months. Immunosuppressive treatment promoted an improvement in cardiac function in 88% of the cases compared with none of the patients in the placebo group, which were switched to a 6-month immunosuppressive therapy at the end of the 6-month study period. Long-term (up to 20 years) clinical outcomes of the whole cohort of 85 patients originally enrolled in the TIMIC trial (Group A) were compared with those of a 1:2 propensity score-matched control cohort of patients untreated with the TIMIC protocol (Group B) and followed for a comparable period of time. The primary outcome was a composite of cardiovascular death and heart transplantation. At long-term follow-up, the risk of cardiovascular death [hazard ratio (HR) 6.77; 95% confidence interval (CI) 2.36-19.45] and heart transplantation (HR 7.92; 95% CI 1.80-34.88) was significantly higher in Group B patients. Group A showed a persistent improvement in the left ventricular ejection fraction compared with Group B (HR 7.24; 95% CI 3.05-17.18). A higher number of Group B patients underwent implantable cardioverter defibrillator implantation. The incidence of recurrent myocarditis was similar between groups, and patients with evidence of a recurrent cardiac inflammatory process promptly responded to a TIMIC protocol application. CONCLUSION: Virus-negative inflammatory cardiomyopathy benefits from immunosuppressive therapy even after long-term follow-up. Recurrence appears to respond to a new TIMIC protocol application.
No takes yet. Share an insight, caveat, or question.
Chimenti et al. (2022) conducted a cohort in Virus-negative chronic inflammatory cardiomyopathy (n=255). Immunosuppressive therapy (prednisone and azathioprine, TIMIC protocol) vs. Optimal conventional heart failure therapy alone (untreated with TIMIC protocol) was evaluated on Composite of cardiovascular death and heart transplantation (p=<0.001). Immunosuppressive therapy with the TIMIC protocol reduced the long-term composite of cardiovascular death and heart transplantation compared to conventional therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: